{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T21:47:34Z","timestamp":1782251254708,"version":"3.54.5"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"crossref","award":["RC2025"],"award-info":[{"award-number":["RC2025"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Therapeutic drug monitoring (TDM) is recommended for optimizing teicoplanin therapy, given its high pharmacokinetic variability. Recent literature suggests that standard dosing regimens are often insufficient to achieve therapeutic targets in pediatric patients. We aimed to evaluate real-world teicoplanin exposure, target attainment, and safety in a cohort of hospitalized children treated with standard dosing, incorporating an estimation of the unbound (free) pharmacologically active fraction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      We conducted a retrospective cohort study at a tertiary pediatric care center (March 2018\u2012September 2022). Patients received standard dosing (loading dose 10 mg\/kg q12h \u00d7 3, followed by maintenance). Trough concentrations (C\n                      <jats:sub>trough<\/jats:sub>\n                      ) were measured postloading dose (day 3). The cohort was stratified by age (0\u20122 versus older than 2 years). Unbound teicoplanin concentrations (\n                      <jats:italic toggle=\"yes\">f<\/jats:italic>\n                      C\n                      <jats:sub>trough<\/jats:sub>\n                      ) were estimated using the Yano prediction model based on albumin levels.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 63 TDM episodes from 52 patients were analyzed. The median total C\n                      <jats:sub>trough<\/jats:sub>\n                      was 57 mg\/L (IQR 38\u201284), significantly exceeding conventional therapeutic targets (10\u201230 mg\/L). Target attainment (C\n                      <jats:sub>trough<\/jats:sub>\n                      minimum threshold &gt;10 mg\/L) was achieved in 96.8% of cases. Patients aged 0\u20132 years exhibited significantly higher total concentrations compared with older children (median 69 versus 41 mg\/L;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.003) and higher estimated free concentrations (median 8.89 versus 5.77 mg\/L;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.008). Despite 47.6% of samples exceeding the reported toxicity threshold of 60 mg\/L, no nephrotoxicity or adverse events were observed. No significant correlation was found between C\n                      <jats:sub>trough<\/jats:sub>\n                      and estimated glomerular filtration rate, whereas a positive correlation with albumin was confirmed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>In this pediatric cohort, standard teicoplanin dosing resulted in early and high target attainment, challenging the notion that current regimens are widely subtherapeutic. The observed high total concentrations were well-tolerated, likely because the estimated free fraction remained within a safe range due to preserved albumin levels. Our findings support the safety and efficacy of standard dosing but highlight significant age-related pharmacokinetic variability, reinforcing the need for TDM protocols that integrate albumin monitoring to guide precision dosing.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001478","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T21:00:28Z","timestamp":1780002028000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["\u201cStandard\u201d Is More Than Enough: Therapeutic Drug Monitoring Confirms Early Target Attainment of Teicoplanin Regimens in Pediatric Patients"],"prefix":"10.1097","author":[{"given":"Marcello","family":"Mariani","sequence":"first","affiliation":[{"name":"Infectious Diseases Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Cafaro","sequence":"additional","affiliation":[{"name":"Unit of Biochemistry, Pharmacology and Newborn Screening, Central Laboratory of Analysis, IRCCS Istituto Giannina Gaslini, Genoa, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia M.","family":"Orsi","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genoa, Genoa, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giammarco","family":"Baiardi","sequence":"additional","affiliation":[{"name":"Pharmacology and Toxicology Unit, Department of Internal Medicine, University of Genoa, Genoa, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1148-427X","authenticated-orcid":false,"given":"Sebastiano","family":"Barco","sequence":"additional","affiliation":[{"name":"Unit of Biochemistry, Pharmacology and Newborn Screening, Central Laboratory of Analysis, IRCCS Istituto Giannina Gaslini, Genoa, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Pigliasco","sequence":"additional","affiliation":[{"name":"Unit of Biochemistry, Pharmacology and Newborn Screening, Central Laboratory of Analysis, IRCCS Istituto Giannina Gaslini, Genoa, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Ricci","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Saffioti","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Bandettini","sequence":"additional","affiliation":[{"name":"Unit of Biochemistry, Pharmacology and Newborn Screening, Central Laboratory of Analysis, IRCCS Istituto Giannina Gaslini, Genoa, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Mesini","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Mattioli","sequence":"additional","affiliation":[{"name":"Pharmacology and Toxicology Unit, Department of Internal Medicine, University of Genoa, Genoa, Italy;"},{"name":"Clinical Pharmacology Unit, Ente Ospedaliero Ospedali Galliera, Genoa, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Moscatelli","sequence":"additional","affiliation":[{"name":"Pediatric and Neonatal Intensive Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"Cangemi","sequence":"additional","affiliation":[{"name":"Unit of Biochemistry, Pharmacology and Newborn Screening, Central Laboratory of Analysis, IRCCS Istituto Giannina Gaslini, Genoa, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elio","family":"Castagnola","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"R1-20260623","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1097\/INF.0000000000002854","article-title":"Resistance to antibiotics of uropathogen bacteria isolated from urine and blood in pediatric cancer patients: a single Center, 12-year study","volume":"39","author":"Landi","year":"2020","journal-title":"Pediatr Infect Dis J"},{"key":"R2-20260623","first-page":"1","article-title":"Antibiotic resistant bloodstream infections in pediatric patients receiving chemotherapy or hematopoietic stem cell transplant: factors associated with development of resistance, intensive care admission mortality","volume":"10","author":"Castagnola","year":"2021","journal-title":"Antibiot (Basel)"},{"key":"R3-20260623","doi-asserted-by":"crossref","first-page":"675","DOI":"10.3390\/pathogens13080675","article-title":"The etiology of bloodstream infections at an Italian pediatric tertiary care hospital: a 17-Year-Long series","volume":"13","author":"Russo","year":"2024","journal-title":"Pathogens"},{"key":"R4-20260623","doi-asserted-by":"crossref","first-page":"769","DOI":"10.3390\/antibiotics10070769","article-title":"Pharmacokinetics of Non-\u03b2-Lactam \u03b2-Lactamase inhibitors","volume":"10","author":"Luci","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"R5-20260623","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.3390\/antibiotics11121769","article-title":"Antibiotic therapy in the critically ill with acute renal failure and renal replacement therapy: a narrative review","volume":"11","author":"Corona","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"R6-20260623","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jiac.2020.06.006","article-title":"Teicoplanin and therapeutic drug monitoring: an update for optimal use in different patient populations","volume":"26","author":"Pea","year":"2020","journal-title":"J Infect Chemother"},{"key":"R7-20260623","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/1120009X.2017.1377909","article-title":"Pharmacokinetic\/pharmacodynamic parameters for treatment optimization of infection due to antibiotic resistant bacteria: a summary for practical purposes in children and adults","volume":"30","author":"Gustinetti","year":"2018","journal-title":"J Chemother"},{"key":"R8-20260623","first-page":"347","article-title":"Indications for the harmonization of the therapeutic intervals of antibacterial drugs","volume":"46","author":"Cangemi","year":"2022","journal-title":"Biochim Clin"},{"key":"R9-20260623","doi-asserted-by":"crossref","first-page":"110728","DOI":"10.1016\/j.clinbiochem.2024.110728","article-title":"Dose optimization and target attainment of vancomycin in children","volume":"125","author":"Cafaro","year":"2024","journal-title":"Clin Biochem"},{"key":"R10-20260623","doi-asserted-by":"crossref","first-page":"276","DOI":"10.7164\/antibiotics.31.276","article-title":"Teichomycins, new antibiotics from Actinoplanes teichomyceticus Nov. Sp. I. Description of the producer strain, fermentation studies and biological properties","volume":"31","author":"Parenti","year":"1978","journal-title":"J Antibiot (Tokyo)"},{"key":"R12-20260623","doi-asserted-by":"crossref","first-page":"106381","DOI":"10.1016\/j.ijantimicag.2021.106381","article-title":"Pharmacokinetics and pharmacodynamics of antibiotics in cystic fibrosis: a narrative review","volume":"58","author":"Castagnola","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"R13-20260623","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s40262-020-00945-4","article-title":"Population pharmacokinetics of unbound and total teicoplanin in critically ill pediatric patients","volume":"60","author":"Aulin","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"R14-20260623","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0891-5520(03)00065-5","article-title":"Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid","volume":"17","author":"Craig","year":"2003","journal-title":"Infect Dis Clin North Am"},{"key":"R15-20260623","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/jac\/45.6.835","article-title":"Teicoplanin therapy for Staphylococcus aureus septicaemia: relationship between pre-dose serum concentrations and outcome","volume":"45","author":"Harding","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"R16-20260623","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jiac.2013.08.006","article-title":"High-dose regimen to achieve novel target trough concentration in teicoplanin","volume":"20","author":"Ueda","year":"2014","journal-title":"J Infect Chemother"},{"key":"R17-20260623","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1093\/jac\/dkq266","article-title":"Analyses of teicoplanin concentrations from 1994 to 2006 from a UK assay service","volume":"65","author":"Tobin","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"R18-20260623","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1093\/jac\/dkab499","article-title":"Clinical practice guidelines for therapeutic drug monitoring of teicoplanin: a consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring","volume":"77","author":"Hanai","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"R19-20260623","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1093\/jac\/dkaf012","article-title":"Population pharmacokinetic analysis of teicoplanin in paediatric patients, including those receiving continuous kidney replacement therapy: a prospective cohort study","volume":"80","author":"Butrague\u00f1o-Laiseca","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"R20-20260623","doi-asserted-by":"crossref","first-page":"674.e7","DOI":"10.1016\/j.cmi.2017.02.032","article-title":"Population pharmacokinetics of teicoplanin and attainment of pharmacokinetic\/pharmacodynamic targets in adult patients with haematological malignancy","volume":"23","author":"Byrne","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"R21-20260623","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.jiac.2021.10.023","article-title":"Enhanced loading dose of teicoplanin for three days is required to achieve a target trough concentration of 20 \u03bcg\/mL in patients receiving continuous venovenous haemodiafiltration with a low flow rate","volume":"28","author":"Ueda","year":"2022","journal-title":"J Infect Chemother"},{"key":"R22-20260623","doi-asserted-by":"crossref","first-page":"e0156824","DOI":"10.1128\/aac.01568-24","article-title":"Population pharmacokinetics and dosing optimization of teicoplanin in renal transplant patients","volume":"69","author":"Zhou","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"key":"R23-20260623","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1097\/INF.0000000000001456","article-title":"Evaluation of teicoplanin trough values after the recommended loading dose in children with associated safety analysis","volume":"36","author":"Yamada","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"R24-20260623","first-page":"2318","article-title":"Age- and gender-related differences in teicoplanin levels in paediatric patients","volume":"68","author":"Strenger","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"R25-20260623","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.pcl.2022.07.001","article-title":"Assessment of kidney function in children","volume":"69","author":"den Bakker","year":"2022","journal-title":"Pediatr Clin North Am"},{"key":"R26-20260623","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/FTD.0000000000000930","article-title":"Optimal teicoplanin dosing regimen in neonates and children developed by leveraging real-world clinical information","volume":"44","author":"Yamada","year":"2022","journal-title":"Ther Drug Monit"},{"key":"R27-20260623","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1007\/s12325-024-02884-z","article-title":"Early therapeutic drug monitoring optimizes teicoplanin use in febrile neutropenic patients with hematological malignancies","volume":"41","author":"Wang","year":"2024","journal-title":"Adv Ther"},{"key":"R28-20260623","doi-asserted-by":"crossref","first-page":"113273","DOI":"10.1016\/j.jpba.2020.113273","article-title":"A liquid chromatography-tandem mass spectrometry platform for the routine therapeutic drug monitoring of 14 antibiotics: application to critically ill pediatric patients","volume":"186","author":"Barco","year":"2020","journal-title":"J Pharm Biomed Anal"},{"key":"R30-20260623","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/FTD.0b013e3180690755","article-title":"Variability in teicoplanin protein binding and its prediction using serum albumin concentrations","volume":"29","author":"Yano","year":"2007","journal-title":"Ther Drug Monit"},{"key":"R31-20260623","doi-asserted-by":"crossref","first-page":"6920","DOI":"10.1128\/AAC.03685-14","article-title":"Population pharmacokinetics of teicoplanin in children","volume":"58","author":"Ramos-Mart\u00edn","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"R32-20260623","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/jcpt.13366","article-title":"Optimal trough concentration of teicoplanin for the treatment of methicillin-resistant Staphylococcus aureus infection: a systematic review and meta-analysis","volume":"46","author":"Hanai","year":"2021","journal-title":"J Clin Pharm Ther"},{"key":"R33-20260623","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s10156-010-0105-1","article-title":"An initial dosing method for teicoplanin based on the area under the serum concentration time curve required for MRSA eradication","volume":"17","author":"Kanazawa","year":"2011","journal-title":"J Infect Chemother"},{"key":"R34-20260623","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1093\/jac\/dkx289","article-title":"Pharmacodynamics of teicoplanin against MRSA","volume":"72","author":"Ramos-Mart\u00edn","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"R35-20260623","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1007\/s00467-023-06275-4","article-title":"Creatinine-based formulas are not ideal to estimate glomerular filtration rate in selected pediatric patients: data from a tertiary pediatric nephrology center","volume":"39","author":"Roussel","year":"2024","journal-title":"Pediatr Nephrol"},{"key":"R36-20260623","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s10156-004-0339-X","article-title":"In vitro protein binding of teicoplanin to neonatal serum","volume":"10","author":"Sando","year":"2004","journal-title":"J Infect Chemother"},{"key":"R37-20260623","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.2147\/IDR.S272982","article-title":"Therapeutic drug monitoring and nephrotoxicity of teicoplanin therapy in Chinese children: a retrospective study","volume":"13","author":"Sun","year":"2020","journal-title":"Infect Drug Resist"},{"key":"R38-20260623","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/bcpt.13679","article-title":"Clinical predictors of nephrotoxicity associated with teicoplanin: meta-analysis and meta-regression","volume":"130","author":"Hirai","year":"2022","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"R39-20260623","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/cts.13484","article-title":"Model-informed precision dosing of teicoplanin for the rapid achievement of the target area under the concentration-time curve: a simulation study","volume":"16","author":"Oda","year":"2023","journal-title":"Clin Transl Sci"},{"key":"R40-20260623","doi-asserted-by":"crossref","first-page":"e00707-17","DOI":"10.1128\/AAC.00707-17","article-title":"Tools for the individualized therapy of teicoplanin for neonates and children","volume":"61","author":"Ramos-Mart\u00edn","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"R41-20260623","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1053\/j.ackd.2017.10.002","article-title":"Alternatives for the bedside schwartz equation to estimate glomerular filtration rate in children","volume":"25","author":"Pottel","year":"2018","journal-title":"Adv Chronic Kidney Dis"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001478","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T21:00:50Z","timestamp":1782248450000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":39,"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001478","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"assertion":[{"value":"2026-02-10","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}